비임상

HOME > 연구실적 > 비임상 > 논문
 
작성일 : 16-03-13 11:06
논문번호 67
논문제목(영문) Comparison of phytoncide with sirolimus as a novel drug candidate for drug-eluting stent.
국내외구분 국외 SCI여부 SCI(E)
연구책임자역할 공저자
주저자명 Kang SN, Kim SE
교신저자명 Han DK
공동저자명 Kang SN, Kim SE, Choi J, Park K, Goo JH, Sim DS, Hong YJ, Kim JH, Joung YK, Lee J, Jeong MH, Han DK;
게제년월일 2014-12-16
ISSN 0142-9612
Impact Factor 8.577
학술지명 Biomaterials
서지사항 0집 / 44권 / 1호,   페이지(1 - 10)
요약초록문
(Abstract) 입력		 A drug-eluting stent (DES) is one of the commonly used treatment techniques in percutaneous coronary intervention (PCI). Sirolimus (SRL) has been widely used for DES as a drug for suppressing neointimal hyperplasia causing restenosis. Phytoncides (PTC) are compounds released from trees and plants, and their solutions contain monoterpenoids such as α-pinene, careen, and myrceen. Some studies have reported that these components exhibit antioxidant, antimicrobial, and anti-inflammatory activities. We hypothesized that PTC may become an alternative drug to SRL for DES, exhibiting alleviated side effects as compared to SRL. A PTC-incorporated stent was compared with an SRL-incorporated stent in terms of physicochemical, pharmacokinetic, and biological properties. In in vitro studies, the effects of each drug on cells were investigated. The results showed that both drugs exhibited similar cytotoxicity, anti-inflammation, and antiproliferation effects. However, these effects resulted from different mechanisms associated with cells, as seen in the immunofluorescence result. An in vivo assay showed that the lumen area was significantly larger and the neointimal area was significantly smaller in SRL- and PTC-loaded stents compared to a drug-unloaded stent. These results suggest that phytoncide can be a feasible alternative drug to SRL for advanced DES although more studies are needed.
파일  B67.+Biomaterials.+2015;(44)1-10..pdf (2.1M) DATE : 2021-05-21 11:20:29